Breaking News Instant updates and real-time market news.

GREK

Global X MSCI Greece ETF

$9.96

(0.00%)

, DB

Deutsche Bank

$8.03

(0.00%)

09:40
07/08/19
07/08
09:40
07/08/19
09:40

Unusually active option classes on open July 8th

Unusual total active option classes on open include: GlobalFTSE Greece (GREK), Deutsche Bank (DB), iShares Nasdaq Biotechnology Index Fund (IBB), Walgreen Boots (WBA), Delta Air Lines (DAL), Bristol Myers Squibb (BMY), Macy's (M), Apple (AAPL), Baidu (BIDU), and Intel (INTC).

GREK

Global X MSCI Greece ETF

$9.96

(0.00%)

DB

Deutsche Bank

$8.03

(0.00%)

IBB

iShares Nasdaq Biotechnology Index

$109.31

(0.00%)

WBA

Walgreens Boots Alliance

$55.18

(0.00%)

DAL

Delta Air Lines

$58.69

(0.00%)

BMY

Bristol-Myers

$45.89

(0.00%)

M

Macy's

$21.64

(0.00%)

AAPL

Apple

$204.19

(0.00%)

BIDU

Baidu

$116.29

(0.00%)

INTC

Intel

$48.09

(0.00%)

  • 09

    Jul

  • 11

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 16

    Sep

GREK Global X MSCI Greece ETF
$9.96

(0.00%)

DB Deutsche Bank
$8.03

(0.00%)

05/20/19
05/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. American Airlines (AAL) downgraded to Underweight from Equal Weight at Morgan Stanley while Delta Air Lines (DAL) was downgraded to Equal Weight from Overweight. 2. Deutsche Bank (DB) downgraded to Sell from Neutral at UBS with the firm saying the bank is facing limited strategic options and its operating conditions are unlikely to improve in the near term amid intense competition. 3. Eaton Vance (EV) double downgraded to Underperform from Buy at BofA/Merrill with analyst Michael Carrier lowering estimates to reflect slower flow trends, a difficult product mix, and potential margin pressures ahead. 4. ProAssurance (PRA) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying the stock has rallied 9% since the company's "disappointing" Q1 results. 5. Clorox (CLX) downgraded to Hold from Buy at Argus with analyst John Staszak citing the company's revenue deceleration reported in Q3 to "just 2%" as well as its near-term growth outlook cut to 2%-3% from 2%-4%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
RBCM
07/08/19
NO CHANGE
RBCM
Underperform
Deutsche Bank business review 'more radical than expected', says RBC Capital
RBC Capital analyst Anke Reingen raised her price target on Deutsche Bank to EUR8 from EUR7.50, saying its transformation plan announced over the weekend is "more radical than expected" and could support its shares over the short term. The analyst maintained her Underperform rating however, noting that the bank's execution will be key, while also pointing to the company's pushed out projections for improvement in profitability.
07/08/19
BOFA
07/08/19
NO CHANGE
BOFA
Underperform
BofA keeps Underperform rating on Deutsche Bank, says capital still an issue
After Deutsche Bank released its outline of its new plan to improve profitability, BofA Merrill Lynch analyst Andrew Stimpson said the cost ambitions are greater than he expected, but he believes capital will continue to be an issue as the bank decided to not raise equity. Also, preliminary Q2 underlying results missed consensus, noted Stimpson, who keeps an Underperform rating on Deutsche Bank shares with many details of the company's plan still outstanding.
05/20/19
UBSW
05/20/19
DOWNGRADE
UBSW
Sell
Deutsche Bank downgraded to Sell from Neutral at UBS
UBS downgraded Deutsche Bank to Sell from Neutral and lowered its price target for the shares to EUR 5.70 from EUR 7.80. The bank is facing limited strategic options and its operating conditions are unlikely to improve in the near term amid intense competition, UBS tells investors in a research note.
IBB iShares Nasdaq Biotechnology Index
$109.31

(0.00%)

WBA Walgreens Boots Alliance
$55.18

(0.00%)

06/28/19
06/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating. 2. Biogen (BIIB) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term." 3. Live Nation (LYV) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying he still likes the company's growth prospects and "consistent" operating performance. 4. Arrowhead (ARWR) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Elemer Piros saying he views the stock as fairly valued. 5. Darden (DRI) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
RAJA
05/14/19
NO CHANGE
RAJA
Walgreens could target Amerisource, LabCorp if it seeks M&A, says Raymond James
Raymond James analyst John Ransom said he thinks that "the temptation" for Walgreens (WBA) to do "something" in terms of M&A will grow over time and the "something" it may consider could include either acquiring AmerisourceBergen (ABC) or LabCorp (LH). His analysis points to LabCorp being a less complicated, "but much less accretive," deal, said Ransom. Given Walgreens' existing ownership of about a 26% stake in AmerisourceBergen, he estimates 16% accretion from buying the company for $95 per share in cash if he assumes $500M of synergies and $2B of opioid fines financed with debt, the analyst tells investors. Though such a deal would make financial sense, he does not think investors would "be overly excited about the strategic upside," Ransom tells investors. While he argues that LabCorp "offers more strategic upside," such a hypothetical deal also has less financial benefit, according to Ransom.
06/27/19
RAJA
06/27/19
NO CHANGE
RAJA
Walgreens Boots Alliance Q3 better than expected, says Raymond James
Raymond James analyst John Ransom maintained a Market Perform rating on Walgreens Boots Alliance after the company reported Q3 earnings results that were modestly better than expected, driven by strong pharmacy sales, along with "roughly flat" FY19 guidance which the analyst believes reflects ongoing headwinds from reimbursement and market challenges.
06/28/19
FBCO
06/28/19
DOWNGRADE
Target $60
FBCO
Neutral
Walgreens Boots Alliance assumed at Neutral from Outperform at Credit Suisse
Credit Suisse analyst A.J. Rice assumed coverage of Walgreens Boots Alliance with a Neutral rating, down from the firm's prior Outperform rating, and set a $60 price target on the stock, down from the firm's prior $70 target. Rice noted that Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating.
DAL Delta Air Lines
$58.69

(0.00%)

06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
JPMorgan notes airline fare hike, doesn't see domestic 'resilience' as priced in
JPMorgan analyst Jamie Baker said he was "surprised" to see domestic fares rising again after a price hike five weeks ago, noting that Southwest (LUV) joined with an increase overnight. Given "the crescendo of inquiries as to why, and nary a question on fares," Baker said he is confident that increased domestic fare resilience is not yet priced into airline stocks. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Spirit Airlines (SAVE) and United Continental (UAL).
07/03/19
STFL
07/03/19
NO CHANGE
Target $90
STFL
Buy
Delta one of biggest beneficiaries of longer MAX grounding, says Stifel
Stifel analyst Joseph DeNardi noted that Delta's (DAL) updated Q2 guidance yesterday was "strong across the board," pointing out that domestic load factor for the quarter of 89% benefited from the fact that the grounding of Boeing's (BA) MAX fleet is keeping industry capacity growth constrained. He sees Delta as one of the biggest beneficiaries, second only to Spirit Airlines (SAVE) and Alaska Air (ALK), as the grounding extends further out given the company's lack of exposure and the industry's competitive capacity dynamics. DeNardi maintains a Buy rating and $90 price target on Delta shares.
07/03/19
SPHN
07/03/19
INITIATION
Target $70
SPHN
Overweight
Delta Air Lines re-assumed with an Overweight at Stephens
Stephens analyst Jack Atkins re-assumed coverage of Delta Air Lines with an Overweight rating and $70 price target, up from his prior target of $68. He thinks the U.S. passenger airline market is "solidly outperforming the doom and gloom expectations that many had at the start of the year" and cites Delta's fare momentum, cost controls and recently extended co-branded credit card agreement as reasons for his bullish view.
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
American, Southwest raised domestic rates in last two days, says JPMorgan
JPMorgan analyst Jamie Baker said American Airlines (AAL) took a "plain vanilla" domestic fare increase of $5 one-way yesterday morning, which was followed by what looks like a system-wide increase from Hawaiian (HA) and a "substantive" Lower 48 increase from Southwest (LUV). He was not expecting another increase so soon after the industry took a broad-based domestic increase in the second week of May, noted Baker, who thinks evidence of domestic demand and potential Q2 guidance increases could reverse "recent apathy" towards the airline space. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
BMY Bristol-Myers
$45.89

(0.00%)

05/28/19
GSCO
05/28/19
DOWNGRADE
Target $60
GSCO
Sell
Goldman sees negative sales growth for Gilead, downgrades shares to Sell
Goldman Sachs analyst Terence Flynn downgraded Gilead Sciences (GILD) to Sell from Neutral and lowered his price target for the shares to $60 from $70. The analyst expects Gilead's sales growth to decelerate saying the Truvada/Atripla loss of exclusivities in Sept ember 2020 represents a $3B headwind. Further, Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition, Flynn tells investors in a research note. As a result, the analyst models annual revenue growth for Gilead through 2022 as negative 5%, which he notes is among the lowest in his coverage universe. Meanwhile, the stock trades at a slight premium to other stocks such as Bristol-Myers (BMY) and AbbVie (ABBV), says Flynn.
06/25/19
WBLR
06/25/19
NO CHANGE
WBLR
Outperform
Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair
William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.
06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
M Macy's
$21.64

(0.00%)

05/08/19
CLVD
05/08/19
NO CHANGE
CLVD
Neutral
Macy's Q1 owned comps estimate lowered at Cleveland Research
Cleveland Research analyst Rusty Wilson lowered his Q1 owned comp store sales estimate for Macy's to down 0.5% from flat, citing weather headwinds and soft trends during Easter and the company's "Friends & Family" event. He noted that consensus calls for a 0.1% decline in owned comps in Q1. Wilson, who also thinks gross margin will be pressured by elevated markdowns and promotions in Q1, keeps a Neutral rating on Macy's shares.
05/16/19
05/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Neutral from Sell at Goldman Sachs with analyst Alexandra Walvis saying she sees a more balanced risk/reward in the wake of the stock's recent underperformance. 2. SAIC (SAIC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso saying he has "growing comfort" with the company's ongoing integration of its Engility acquisition and sees the deal producing a "notable improvement" in free cash flow. 3. Scorpio Tankers (STNG) upgraded to Overweight from Neutral at JPMorgan with analyst Noah Parquette saying he's seen a considerable increase in interest from investors in the IMO 2020 product tanker story in recent weeks. 4. KB Home (KBH) and Taylor Morrison (TMHC) were upgraded to Outperform from Sector Perform at RBC Capital. 5. MYR Group (MYRG) upgraded to Buy from Hold at Stifel with analyst Noelle Dilts saying she sees "compelling dynamics" in the electric transmission and distribution market as utilities move investment toward power delivery in order to address reliability concerns, the need for grid hardening, and aging infrastructure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/19
MSCO
05/16/19
NO CHANGE
Target $20
MSCO
Underweight
Macy's EPS beat masks 'worrying' core retail performance, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said the 11c EPS beat reported by Macy's compared to consensus was driven by lower taxes, real estate gains and credit card revenue growth outperformance. However, she estimates that Macy's had a 0% core retail operating margin in Q1 and noted that its trend of shrinking core retail EBIT dollars, which began in 2015, has continued. The company's same-store comparisons were the easiest of the year in Q1 and Macy's laps significantly more difficult comparisons in the second half, said Greenberger, who sees "little room for error." She maintains an Underweight rating on Macy's shares and lowered her price target on the stock to $20 from $22 after lowering her 2022 and 2023 gross margin estimates due to expectations for higher e-commerce delivery expenses.
05/16/19
GSCO
05/16/19
UPGRADE
Target $21
GSCO
Neutral
Macy's upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis upgraded Macy's to Neutral from Sell while lowering her price target for the shares to $21 from $23. Following the company's Q1 results, the analyst sees a more balanced risk/reward in the wake of the stock's recent underperformance. Since her Sell initiation on September 3, 2018, Macy's shares have fallen 41%. While the company continues to face "fading fundamentals" in the medium term as secular challenges weigh, the stock's near term risk/reward is now less skewed to the downside, Walvis tells investors in a research note. Further, she believes Macy's planned quantification of its cost savings program this fall and a potential update on the monetization of Herald Square as potential near-term catalysts for the shares.
AAPL Apple
$204.19

(0.00%)

07/02/19
SBSH
07/02/19
NO CHANGE
Target $205
SBSH
Buy
Apple consensus estimates are likely too high, says Citi
Citi analyst Jim Suva expects share price volatility in the months ahead for Apple as consensus estimates calibrate lower. Within China Apple has 12% unit share and these unit shipments could be cut in half, Suva tells investors in a research note. The analyst, however, remains optimistic on the Services segment with Apple Arcade to launch in the second half of 2019. Suva does not see multiple compression for Apple, "but rather see risk that consensus is simply too high." Despite his expectations for share volatility, the analyst keeps a Buy rating on Apple with a $205 price target. Suva points out that consensus estimates for Apple's fiscal Q3, or June, quarter are towards the mid-end of guidance with revenues at $53.35B and earnings per share at $2.10 while his estimates are lower at $52.6B and $2.06, respectively.
07/08/19
RSBL
07/08/19
DOWNGRADE
Target $150
RSBL
Sell
Apple downgraded to Sell from Neutral at Rosenblatt
Rosenblatt analyst Jun Zhang downgraded Apple to Sell from Neutral with an unchanged price target of $150.
07/08/19
WEDB
07/08/19
NO CHANGE
Target $235
WEDB
Outperform
Wedbush sees Asian checks giving confidence in Apple iPhone demand despite noise
Wedbush analyst Daniel Ives says that his firm's Asia checks over the past week suggest stable Apple iPhone demand globally heading into the crucial September quarter with some puts and takes that overall he would characterize as "better than feared" in light of the noisiest time he could remember for Cupertino. While China remains a wild card, the analyst is bullish into Apple's future heading into FY20 and beyond. Ives reiterates an Outperform rating and $235 price target on the shares.
07/08/19
RSBL
07/08/19
DOWNGRADE
Target $150
RSBL
Sell
Rosenblatt sees Apple fundamentals deteriorating, downgrades to Sell
Rosenblatt analyst Jun Zhang downgraded Apple to Sell from Neutral, citing his view that its fundamental will deteriorate over the next 6-12 months. Zhang believes new iPhone sales will be disappointing, iPad sales growth will slow in the second half of 2019, and that service revenue growth will also decelerate. His analysis of retail data suggests overall iPhone sales were flat month-over-month in June and he expects major iPhone upgrades to be pushed out to the second half of 2020 given what are seen as limited upgrades for the new iPhone models in the fall and expectations of a 5G iPhone in 2020. While Zhang cut his rating to Sell, he does not see Apple as a stock to short, noting that the company has "plenty of cash and a meaningful stock buy back program," the analyst added. Zhang keeps a $150 price target on Apple shares, which are down $2.86, or 1.4%, to $201.37 in pre-market trading.
BIDU Baidu
$116.29

(0.00%)

05/20/19
UBSW
05/20/19
DOWNGRADE
UBSW
Neutral
Baidu downgraded to Neutral from Buy at UBS
06/28/19
JPMS
06/28/19
DOWNGRADE
Target $3.5
JPMS
Underweight
JPMorgan cautious on China ad recovery, downgrades Sogou, cuts Baidu target
JPMorgan analyst Alex Yao last night downgraded Sogou (SOGO) to Underweight from Neutral and lowered his price target for the shares to $3.50 from $5.50. The analyst says he found no evidence to support the "widely adopted optimism" on an advertising growth recovery in the second half of 2019 for the China Internet sector. As a result, he's cautious on names with high exposure to online ads, or Baidu (BIDU), Weibo (WB), Sogou, Focus Media, Autohome (ATHM), and Bitauto (BITA). Yao downgraded both Sogou and Focus Media to Underweight and lowered his price target for Neutral-rated Baidu to $120 from $150.
06/03/19
LOOP
06/03/19
INITIATION
Target $125
LOOP
Hold
Baidu initiated with a Hold at Loop Capital
Loop Capital started Baidu with a Hold rating and $125 price target.
06/04/19
LOOP
06/04/19
INITIATION
Target $125
LOOP
Hold
Baidu initiated with a Hold at Loop Capital
As previously reported, Loop Capital analyst Rob Sanderson initiated Baidu with a Hold rating and a price target of $125. The analyst sees Baidu as a "strong technology company" offering "multiple long-term upside options", but also points to the soft macro conditions and a more competitive environment for its product. Sanderson wants to see improved visibility in the company's core business, adding that while its enterprise AI, voice search and autonomous vehicle opportunities are "sizable" in the long term, they are not yet "investable" for fund managers.
INTC Intel
$48.09

(0.00%)

07/08/19
KEYB
07/08/19
NO CHANGE
KEYB
Ambarella, Silicon Labs could be next as semiconductor M&A heats up, says KeyBanc
KeyBanc analyst John Vinh believes semiconductor M&A activity is starting to heat up again, and sees diversification into secular growth areas in IoT, automotive, and cloud, and increased scale and customer breadth, as key underlying deal drivers within the space. The analyst expects further consolidation to continue, but notes U.S./China political tensions and uncertainty regarding regulatory approvals could limit larger scale M&A. Companies that could be acquired next include Ambarella (AMBA) or Silicon Labs (SLAB), he contends, while expecting Broadcom (AVGO), Applied Materials (AMAT), Intel (INTC), NXP Semiconductors (NXPI), Skyworks (SWKS), Texas Instruments (TXN), and Xilinx (XLNX) to be the most acquisitive.
06/27/19
06/27/19
INITIATION
Target $37.5

Underperform
Intel initiated with an Underperform on challenges ahead at Wedbush
As previously reported, Wedbush analyst Mathew Bryson initiated Intel with an Underperform and $37.50 price target. The analyst believes Intel's recent struggles with execution combined with cyclical downturns in key markets together create an uncertain future with downside risk to estimates.
06/27/19
06/27/19
INITIATION
Target $30

Neutral
Wedbush cautious on Micron, initiates with a Neutral
As previously reported, Wedbush analyst Mathew Bryson initiated Micron (MU) with a Neutral and $30 price target. The analyst notes that Micron has suffered and continues to suffer from the downturn in memory fundamentals. Bryson remains less positive about 2019 second half fundamentals and to some extent Micron's execution as focus shifts from clear improvements in NAND chip production on the 32 layer and 64 layer nodes toward questions around Micron's ability to execute on charge trap without Intel (INTC), while at the same time needing to build scale in this market to compete effectively with its much larger peers. Net, he is not yet convinced the memory markets have bottomed.
06/27/19
06/27/19
INITIATION
Target $35

Outperform
Wedbush bullish on AMD, initiates with an Outperform
As previously reported, Wedbush analyst Matthew Bryson initiated AMD (AMD) with an Outperform rating and $35 price target. The analyst views AMD's reemergence in CPUs as one of the likely major shifts in both the PC and data center markets over the next few years. Specifically, Bryson believes AMD's early adoption of a distributed "chiplet" architecture combined with a shift to leading edge geometries positions the company to take meaningful share from Intel (INTC) in both the PC and server markets over the next few years. Moreover, he expects AMD will also realize some more modest benefits on the GPU side, with its GPU business also poised to benefit from a resumption of more normalized channel sales, sales into Google (GOOG) Stadia, console transitions, and a recently signed agreement with Samsung (SSNLF) to share and license IP.

TODAY'S FREE FLY STORIES

CMA

Comerica

$69.23

-2.52 (-3.51%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Downgrade
Comerica rating change  »

Comerica downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

EBAY

eBay

$39.03

-0.87 (-2.18%)

05:26
07/18/19
07/18
05:26
07/18/19
05:26
Recommendations
eBay analyst commentary  »

eBay price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.50

-3.22 (-0.88%)

05:23
07/18/19
07/18
05:23
07/18/19
05:23
Recommendations
Netflix analyst commentary  »

Netflix content lineup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$217.73

12.67 (6.18%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Downgrade
ASML rating change  »

ASML downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:20
07/18/19
07/18
05:20
07/18/19
05:20
Earnings
Novartis raises FY19 revenue view to up mid to high-single digit »

Novartis provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Skyworks rating change  »

Skyworks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$203.32

-1.08 (-0.53%)

05:18
07/18/19
07/18
05:18
07/18/19
05:18
Upgrade
Apple rating change  »

Apple upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

SWKS

Skyworks

$80.15

-1.14 (-1.40%)

05:16
07/18/19
07/18
05:16
07/18/19
05:16
Downgrade
Skyworks rating change  »

Skyworks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$75.75

0.09 (0.12%)

05:15
07/18/19
07/18
05:15
07/18/19
05:15
Downgrade
Qualcomm rating change  »

Qualcomm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

VET

Vermilion Energy

$21.12

-0.44 (-2.04%)

05:14
07/18/19
07/18
05:14
07/18/19
05:14
Downgrade
Vermilion Energy rating change  »

Vermilion Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

XOM

Exxon Mobil

$75.49

-0.44 (-0.58%)

05:13
07/18/19
07/18
05:13
07/18/19
05:13
Downgrade
Exxon Mobil rating change  »

Exxon Mobil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TTD

Trade Desk

$244.23

0.72 (0.30%)

05:12
07/18/19
07/18
05:12
07/18/19
05:12
Downgrade
Trade Desk rating change  »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$90.11

0.99 (1.11%)

05:11
07/18/19
07/18
05:11
07/18/19
05:11
Earnings
Novartis reports Q2 core EPS $1.34, consensus $1.22 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

IHG

InterContinental

$69.80

-0.16 (-0.23%)

05:11
07/18/19
07/18
05:11
07/18/19
05:11
Downgrade
InterContinental rating change  »

InterContinental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WTBDY

Whitbread

$0.00

(0.00%)

05:10
07/18/19
07/18
05:10
07/18/19
05:10
Downgrade
Whitbread rating change  »

Whitbread downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$28.85

-0.555 (-1.89%)

05:08
07/18/19
07/18
05:08
07/18/19
05:08
Downgrade
MGM Resorts rating change  »

MGM Resorts downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

EXP

Eagle Materials

$86.46

-0.245 (-0.28%)

05:06
07/18/19
07/18
05:06
07/18/19
05:06
Downgrade
Eagle Materials rating change  »

Eagle Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

  • 21

    Aug

  • 04

    Sep

  • 13

    Nov

ATI

Allegheny Technologies

$24.47

-0.415 (-1.67%)

05:05
07/18/19
07/18
05:05
07/18/19
05:05
Downgrade
Allegheny Technologies rating change  »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

ARNC

Arconic

$25.29

-0.49 (-1.90%)

05:05
07/18/19
07/18
05:05
07/18/19
05:05
Downgrade
Arconic rating change  »

Arconic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USCR

U.S. Concrete

$50.87

-0.96 (-1.85%)

05:04
07/18/19
07/18
05:04
07/18/19
05:04
Downgrade
U.S. Concrete rating change  »

U.S. Concrete downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 13

    Nov

AMD

AMD

$33.59

-0.23 (-0.68%)

, INTC

Intel

$49.39

0.22 (0.45%)

04:59
07/18/19
07/18
04:59
07/18/19
04:59
Downgrade
AMD downgraded to Neutral from Buy at Mizuho »

Mizuho analyst Vijay…

AMD

AMD

$33.59

-0.23 (-0.68%)

INTC

Intel

$49.39

0.22 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

04:55
07/18/19
07/18
04:55
07/18/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 7/13 Jobless…

04:55
07/18/19
07/18
04:55
07/18/19
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

GMRE

Global Medical REIT

$10.51

-0.15 (-1.41%)

04:55
07/18/19
07/18
04:55
07/18/19
04:55
Conference/Events
Global Medical REIT management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

TORC

ResTORbio

$10.42

0.19 (1.86%)

04:55
07/18/19
07/18
04:55
07/18/19
04:55
Conference/Events
ResTORbio management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.